Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Synchrony Medical announced that it received FDA 510 (k) clearance for its LibAirty airway clearance system.

Frequent consumption of a common drug that acts on the nervous system and treats a range of ailments may lead to faster ...

The CAAT governance board recommends transitioning from the COPD Assessment Test to the CAAT and using it for patients with ...

Gabapentin is approved for seizures and post-herpetic neuralgia; gabapentin enacarbil is approved for restless legs syndrome.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

“The brain is the gatekeeper of longevity,” said Wyss-Coray. “If you’ve got an old brain, you have an increased likelihood of ...

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris, ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.